Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lotazadromcel
- Development stage
- Phase 2
- Lead developer
- ElpasBio
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Lotazadromcel, also known as AlloJoin®, is an investigational allogeneic stem cell therapy developed by ElpasBio. It is being developed for the treatment of knee osteoarthritis (KOA). ElpasBio has granted Fosun Kairos exclusive rights to commercialize AlloJoin® in Mainland China, Hong Kong, and Macau, while retaining development, regulatory, manufacturing, and commercial rights in other territories.
- Brand names
- AlloJoin
- Other names
- Allogenic Adipose Tissue-Derived Mesenchymal Stem CellsAllogenic Adipose Tissue-Derived Mesenchymal Progenitor Cellsha-MSCs
Beyond the preview
Go deeper on lotazadromcel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lotazadromcel.